Member Info for BuenaVista

Interesting. This is new technology, base editing. In its infancy still.

Revolutionary therapy clears girl's incurable cancer
https://www.bbc.co.uk/news/health-63859184

Trial details:
Study of Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7) (TvT CAR7)
https://clinicaltrials.gov/ct2/show/NCT05397184

Not mentioned as sponsor for this trial, but seemingly relevant, is Cell Medica Ltd,
https://www.bioindustry.org/member/cell-medica-ltd.html
a company that, together with Technology Strategy Board, United Kingdom, had sponsored a previous trial that Prof Waseem Qasim had led.

This is the maximum doxorubicin that can be given (per dose and per lifetime, 75 and 450). Poor patients, the side effects must be horrendous.

At 200mg/m² AVA6000, the patients are receiving 135mg/m² doxorubicin equivalent (200 x 54 /80) which is nearly twice what the patients on this trial get.

Ah, P&G, the company that gave us the Fabreze advert with the woman flushing the toilet with the lid up and wondering why odours reside in the room. This patent may let you know what form of s**t you've got on the surfaces of your room if you're stupid enough not to put the lid down.

The patent has very broad coverage - all bases covered - which is normal, otherwise someone will make the same but using something not covered, but good to see affimers recognised as an option.

It's all been about well characterised off-patent anticancer drugs.

But what about anticancer drugs that still have patent protection? Does that patent protection truly prevent a pre|CISION prodrug form of the drug being produced by a competitor? Or a pre|CISION prodrug of an (unpatented) active metabolite of the drug?

Perhaps more pertinently, wouldn't a pharma company with an on-patent anticancer drug pay a lot to get hold of a pre|CISION prodrug version of that drug?

How much would that be worth to the pre|CISION platform and Avacta SP?

The media will love targetted doxorubicin with minimal/no side effects. Any efficacy questions (eh?) can wait. Will be obvious that targetted plus vastly reduced side effects equals efficacy for a well recognised cytotoxic agent.

I ike HurstBot's new Loquacious module.

That MoU is 20 months old now. I'm not holding my breath that it will come to anything. Very tempted to go up the road to Dunsfold to find out wtf is happening.

So it looks like Afc will be lumbered with an ENOWA-branded L series white elephant. What possible use can this old technology be?

A cordon bleu chef, no less. Must be expecting some big spenders.

https://www.withpower.com/trial/phase-1-sarcoma-6-2021-6f477

At least 3 patients have applied via the withpower site.

Yes it has been updated.

As of 6 June 2022, it was The Christie
https://web.archive.org/web/20220606100033/https://www.withpower.com/trial/phase-1-sarcoma-6-2021-6f477
Eligible cancer: sarcoma (STS)

It may well have subsequently been the Glasgow hospital as that hospital started recruiting after The Christie.

Yes it has been updated.

As of 6 June 2022, it was The Christie
https://web.archive.org/web/20220606100033/https://www.withpower.com/trial/phase-1-sarcoma-6-2021-6f477
Eligible cancer: sarcoma (STS)

It may well have subsequently been the Glasgow hospital as that hospital started recruiting after The Christie.

Both Phase 1a and 1b covered and all 8 cancer types covered in the 'advert'. However they only seem to be interested in sarcoma and colorectal carcinoma at Newcastle - click to open the 'What conditions do you have?' list.

Great news!

Why do you think the market should be thinking the way you are thinking? The market is clearly not. The market is not 'efficient', certainly not the AIM market. There are not dozens and dozens of analysts poring over every bit of news or hint coming out of Avacta. Very much a wait and see for definite news.

And just to be clear, I don't care what you or any of your fanboys think of me or want to make up about my holdings or intentions.

Wouldn't it be ironic if the follow-on pre|CISION prodrugs licensed out to major pharma companies came onto the market and were providing royalties to Avacta years before Avacta managed to struggle AVA6000 onto the market before the patent life runs out? I'm not comfortable with Avacta taking AVA6000 through all the coordination and complexities - and there are many - of clinical trials and registration with regulatory authorities around the world. You have to ask whether other observers are comfortable with Avacta taking it all on themselves and whether that is affecting the SP.

Plus AVA3996 being variously described as 'Velcade' and then 'Velcade analogue' (which would require full clinical development) and no indication whether the other prodrugs in the pipeline are prodrugs of marketted drugs or prodrugs of their analogues.

There's not enough clarity of Avacta's future prospects to make value judgements.

I think there is also the element of disbelief - if something is too true to be good, then it probably is. We've most likely all experienced cancer affecting family and friends, if not ourselves personally, and we know how horrible the disease is and how horrible the treatment side effects are and how many die or go into remission and then relapse and die. A commonly prescribed drug that has those horrible side effects, yet can be delivered in such a way as to not only remove the side effects but also potentially destroy the cancer? Surely too good to be true? And unless one is well informed about the mode of action and the news relating to the trial one might indeed think that.

As someone (Robin Morgan) once said: "Knowledge is power. Information is power. The secreting or hoarding of knowledge or information may be an act of tyranny camouflaged as humility."

However, as someone else almost said: "You can lead an investor to knowledge but you can't make him think."

And, of course, there are a lot of traders, chartists and fickle investors who don't even care about the underlying business.

Interesting, thanbks.

There are currently 59 grants being funded - just hit 'Run Search' on the search page.

Over the history of the ODD, there have been 691 grants - select 'All Funded Grants (current and previous)' before doing search. Of these nearly all have been for trials by US companies/hospitals/universities in the USA. However about 4 have been for foreign organisations carrying out trials in Canada and 4 outside North America (Holland, Switzerland, France and Vietnam). There may have been one or two others that I missed but it is clear that the FDA occasionally fund foreign organisations to carry out trials in their own country.

As trials in the UK are a lot cheaper than in the US this would go into the decision mix. Trials carried out in the US probably have more kudos and impact on US thinking though.

Are you sure? Where are the other awarded contracts? Reads to me like Launch have the contract (as a distributor for tests that they sell).

"Sounds like us"

Eh?

"A diverse range of clinical research trials are in progress & following training, you will be expected to participate in these studies as a co-/sub-investigator."

As it'll be multitasking, probably a job for woman. ;0)